Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-250,000
Closed -$9.63M 29
2025
Q3
$9.63M Buy
250,000
+57,671
+30% +$1.42M 5.16% 2
2025
Q2
$7.12M Buy
+192,329
New +$4.49M 3.44% 13
2025
Q1
Sell
-150,000
Closed -$3.98M 41
2024
Q4
$3.98M Buy
+150,000
New +$4.07M 3.65% 8

Other funds holding PFE

Arrow Capital's PFE Position: Q4 2025 in Review

Arrow Capital sold out of Pfizer (PFE) in Q4 2025, closing a stake of 250,000 shares — an estimated $9.63M sold.

Arrow Capital first reported a position in PFE in Q4 2024 and held it in 3 quarters. The position peaked at $9.63M in Q3 2025. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Arrow Capital reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Arrow Capital sold 250,000 Pfizer shares in Q4 2025, an estimated $9.63M.
  • Arrow Capital first reported a position in Pfizer in Q4 2024 and held it in 3 quarters.
  • Arrow Capital's Pfizer position peaked at $9.63M in Q3 2025.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Arrow Capital's 13F filing for Q4 2025, filed 17 Feb 2026.